Grants for For profit organizations other than small businesses - Federal

This funding opportunity is designed to support innovative research and development projects that enhance military logistics, supply chain resilience, and operational readiness for the Department of Defense.

This NOFO seeks proposals from eligible applicants for activities to establish and operate a CHIPS Manufacturing USA Institute focused on digital twins with integrated physical assets and computational capabilities (digital assets) to tackle important semiconductor-industry manufacturing challenges. The CHIPS Manufacturing USA Institute will join an existing network of seventeen Institutes designed to increase U.S. manufacturing competitiveness and promote a robust R infrastructure. The Institute will manage a portfolio of Institute-led projects and competitively funded Member-led projects, including Education and Workforce Development (EWD) activities, basic and applied research, and technology demonstrations.

It is well documented that many investments in Africa, including in Liberia, fail to meet internationally accepted standards. This trend continues in part because of host countries lack of awareness, capacity, and governance. This project aims to address these weaknesses by bringing together government, civil society, journalists, academics, and other key stakeholders to build Liberias internal capacity to ensure further investments and projects have improved standards and mechanisms in place to monitor and penalize non-compliance. The project will include components that offer stakeholders: investment best global practices; case studies involving how to advance transparency in negotiating large investment deals in Africa; training/advising government officials on developing legal and regulatory investment frameworks; mentoring on public awareness campaigns around investment standards; and seminars in investigating investment-related challenges and successes in the African context. Projects should target: Countering lending and investment projects that fail to adhere to internationally accepted investment practices and as a result put at risk Liberias sovereignty, socio-economic well-being, and biodiversity.

This funding opportunity provides financial support for research projects that develop and test nonopioid pain management strategies for Veterans and military personnel, focusing on integrating these approaches into standard healthcare practices.

The FY24 PRMRP Lifestyle and Behavioral Health Interventions Research Award (LBIRA) supports clinical research and/or clinical trials using a combination of scientific disciplines including behavioral health, psychology, psychometrics, biostatistics and epidemiology, surveillance, and public health. Applications are required to address and provide a solution to one of the congressionally directed FY24 PRMRP Topic Areas and FY24 PRMRP Strategic Goals.The overall intent of the FY24 PRMRP LBIRA mechanism is to promote evidence-based and patient-centered approaches to improve health and/or disease-related outcomes and enhance the patient experience in defined populations. Research ideas may include, but are not limited to: Development and testing for efficacy of lifestyle interventions and symptom management approaches to minimize disease risk and maximize quality of life. Studies to investigate the impact of prevention, diagnostics, treatment, or health care delivery approaches on health outcomes. Studies to assess the relationship(s) between behavioral, cognitive, and/or social functioning in relation to disease or condition initiation, progression, detection, treatment, and rehabilitation. Studies to examine and improve quality of life or decision-making. Population-focused studies to identify behavioral and lifestyle predictors of disease and/or disease progression.Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.m. Eastern time (ET), May 13, 2024

This funding opportunity supports early-career researchers and medical residents conducting impactful cancer research relevant to military health, with a focus on improving the quality of life for service members and their families.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on diabetes, its complications, and related endocrine and metabolic diseases. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the P30 activity code. Details of the planned NOFO are provided below.

This funding opportunity is designed to support domestic industrial facilities in recovering critical minerals and materials from byproducts, enhancing the U.S. supply chain and reducing reliance on foreign sources.

This funding opportunity provides financial support to organizations that assist workforce systems in improving service delivery, promoting equity, and enhancing outcomes for underserved populations, including people of color and individuals with disabilities.

This funding opportunity provides financial support for domestic organizations to develop innovative technologies that enhance the supply chain for enriched uranium, ensuring its availability for nuclear reactors and strengthening U.S. energy security.

The DoD Bone Marrow Failure, Idea Development Award is a funding opportunity aimed at supporting innovative and scientifically sound research ideas that contribute to understanding and curing bone marrow failure diseases, with a particular emphasis on hypothesis-driven studies linked to clinical trials, open to both established and early-career investigators.

This grant provides funding to early-career researchers dedicated to innovative breast cancer research, emphasizing transformative approaches and collaboration with breast cancer survivors.

With this solicitation, OJJDP seeks to support a National Community and Schools Youth Drug Prevention Program for the purpose of delivering substance use prevention programs in schools in partnership with local law enforcement and community coalitions. The successful national organization will provide funding and training and technical assistance (TTA) to local non-profits who will be required to build community coalitions in partnership with law enforcement to educate youth in schools and in extracurricular programming on drug prevention. Community coalitions consist of community leaders that organize to meet the local prevention needs of the youth and families in their communities. Partnerships among non-profit organizations, community coalitions and law enforcement ensure that communities implement comprehensive approaches to prevent youth substance use.

The National Cancer Institute intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for pilot/exploratory research on the confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This NOFO will utilize the R21 grant mechanism (clinical trial optional), which is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Up to three (3) R21 awards are expected to be funded as part of the initiative. Research projects will advance the current understanding of the confluence of cancer stigma and HIV stigma in people with HIV (PWH) diagnosed with cancer; investigate the resultant impact of these dual stigmas on cancer outcomes among PWH with cancer; and promote research in diverse domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated. Pilot interventional research, which addresses modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer, is also suitable for this funding mechanism. The NOFO is expected to be published in late Summer 2024 with an expected application due date in late Fall 2024. Details of a pre-application webinar will be announced after the publication of the NOFO. This Notice is being provided to allow sufficient time for potential applicants with relevant expertise and insights to consider applying for this NOFO. Potential applicants are encouraged to view the presentation of this initiative to the Joint Virtual Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board available at https://videocast.nih.gov/watch=54859 beginning at 3 hour, 39 minutes. Presentation slides are downloadable at: https://deainfo.nci.nih.gov/advisory/joint/0624/Vanderpool.pdf.

This funding opportunity provides financial support for organizations to conduct research and improve programs that benefit Native American children and families, focusing on early childhood education and family economic well-being.

Maturing research ideas into clinical practice and patient benefit is at the heart of all CDMRP research programs. Despite significant investment, the gap between what is possible and what is achieved remains. Even after information, tools, and interventions have been successfully evaluated in their intended populations, the development of knowledge to support their broader dissemination and implementation has often remained outside the scope. The FY24 TBIPHRP HSRA intends to bridge the gap between research, practice, and policy by building real-world evidence on how interventions, clinical practices/guidelines, and policies can be deployed to targeted populations at the appropriate time.Research Scope: The FY24 HSRA will fund clinical research (including clinical trials). Preclinical and animal research are prohibited. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed. Proposed clinical trials should include interventions, clinical practices/guidelines, and policies that are well-supported within the literature and in relevant patient population(s). This award may not be used to support studies requiring an exception from informed consent (EFIC).Key aspects of the FY24 TBIPHRP HSRA: Precision Medicine Approaches: When appropriate, the TBIPHRP encourages the use of precision medicine approaches. These tailored treatments deliver the right treatment at the right time while considering an individuals unique characteristics. Community-Based Participatory Research: The application must include Community-Based Participatory Research (CBPR) approaches in the development and execution of the clinical research/trial. CBPR approaches should be documented in Attachment 8. Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical research/trial is required. Untested novel interventions are discouraged: Novel interventions that have not been evaluated in the intended population(s) are discouraged. Applicants seeking funding for novel interventions should consider one of the other FY24 TBIPHRP announcements. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Inquiry Review Board [IRB] review) are exempt from this requirement. Clinical Trial Start Date: If applicable, the proposed clinical trial is expected to begin no later than 6 months after the award date. Intervention Availability: If applicable, the application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.The FY24 HSRA applications may include (not all inclusive): Research that accelerates the uptake and implementation of evidence-based research into clinical practice. Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings. Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. Analysis of existing data or resources to inform clinical practice. Modification of established clinical tools for their intended population or environment. Analysis of existing clinical tools to maximize patient-relevant outcomes. Identification and analysis of the circumstances that create a need to stop or reduce (de-implement) the use of interventions, tools, policies, and guidelines that are ineffective, unproven, low-value, or harmful are within scope. Analysis of TBI and/or psychological health outcomes associated with the implementation of clinical practice guidelines, evidence-based practices, and process improvements.Early-Career Investigator Partnering Option: The FY24 TBIPHRP HSRA includes an Early-Career Investigator Partnering Option that is structured to accommodate two Principal Investigators (PIs), one of whom is an Early-Career Investigator. The combined direct costs budgeted for the entire period of performance in the applications of the Initiating PI and Partnering PI should not exceed $2.5M. The PIs may have experience in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. One PI will be identified as the Initiating PI and will be responsible for most of the administrative tasks associated with application submission. The other investigator will be the Partnering PI. At least one of the Initiating or Partnering PIs must be an Early-Career Investigator. The intent is not to create mentor-mentee arrangement. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The application is expected to describe how the PIs unique experience/expertise combined as a partnership will better address the research question, how the unique experience/expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. If recommended for funding, each PI will be named to an individual award within the recipient organization(s). For individual FY24 TBIPHRP HSRA submission requirements for the Initiating and Partnering PI, refer to S Section II.D.2, Content and Form of the Application Submission.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document.pdf.Clinical trials may be designed to evaluate pharmacologic agents (drugs or biologics), diagnostics, devices, therapies, clinical guidance, behavioral interventions, emerging approaches and technologies, and/or new indications for products currently U.S. Food and Drug Administration (FDA)-approved or -cleared. Interventions that are not FDA-regulated (or international equivalent) are within scope but the regulatory status must be documented in Attachment 12, Regulatory Strategy.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Multi-Institutional Clinical Research/Trials: As of January 20, 2020, U.S. institutions engaged in non-exempt cooperative research must rely on a single IRB to review and approve the portion of the research conducted at domestic sites (45 CFR 46.114(b)). If the proposed, non-exempt research involves more than one U.S.-based institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.Communication and data transfer between or among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the application. A separate intellectual and material property plan agreed on by all participating institutions is also required for multi-institutional clinical research/trials.Relevance to Military Health: Relevance to the health care needs of Service Members, their Families, and Veterans is a key feature of this award. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health: Explanation of how the project addresses an aspect of psychological health conditions and/or TBI that has direct relevance to the health and/or readiness of Service Members, their Families, and Veterans. Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to benefit the civilian population and also address a military need. Use of military or Veteran populations, samples, or datasets in the proposed research, if appropriate.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $15.5M to fund approximately four HSRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides financial support for organizations to develop and evaluate innovative strategies aimed at preventing and addressing elder abuse and neglect among older adults and individuals with disabilities.

This grant provides funding for researchers and organizations to analyze data from Mars missions, supporting advancements in our understanding of the planet's geology, climate, and potential for life.

This funding opportunity is designed to support research sites that will enroll patients with Type 1 Diabetes at risk of kidney disease, enabling the study of kidney biopsies to advance understanding and treatment of diabetic nephropathy.

This initiative provides funding opportunities for private sector entities in Jordan to collaborate with USAID in addressing key development challenges, focusing on economic growth, water security, governance, education, and the empowerment of women and youth.